格隆溴铵(Glycopyrrolate) - 药物靶点：mAChRs_在研适应症：麻醉，心律失常，脑瘫_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Extrafine glycopyrronium bromide pMDI、Glycopyrrolate (USP)、Glycopyrrolate inhalation - Chiesi

+ [30]

靶点

mAChRs

作用方式

拮抗剂

作用机制

mAChRs拮抗剂(毒蕈碱型乙酰胆碱受体家族拮抗剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Exela Pharma Sciences LLC

+ [11]

非在研机构

Pearl Therapeutics, Inc.Shionogi, Inc.

Novartis Pharmaceuticals Canada, Inc.

+ [9]

权益机构

Sumitomo Pharma America, Inc.

浙江海正药业股份有限公司

Vectura Group Ltd.

+ [4]

最高研发阶段批准上市

首次获批日期

美国 (1961-08-11),

消化性溃疡

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C19H28BrNO3

InChIKeyVPNYRYCIDCJBOM-HPUDQCTASA-M

CAS号51186-83-5

关联

225

项与格隆溴铵相关的临床试验

CTRI/2025/03/083518

/ Not yet recruiting临床4期IIT

A comparative study determining the effect of pre-emptive intravenousGlycopyrrolate versus Ondansetron in preventing spinal hypotension inpatients undergoing elective inguinal hernioplasty at a tertiary care hospital - NIL

开始日期2025-04-15

申办/合作机构-

ChiCTR2500099381

/ Suspended临床3期IIT

The efficacy and safety of glycopyrronium and neostigmine injection in antagonizing the residual neuromuscular blockade of non-depolarizing muscle relaxants were evaluated in a multi-center, randomized, double-blind, positive-drug parallel controlled phase III clinical trial

开始日期2025-03-28

申办/合作机构

中南大学湘雅三医院

ChiCTR2500097073

/ Suspended临床4期IIT

Comparison of the Effects of Glycopyrrolate and Pentamidine Acetate on Postoperative Nausea and Vomiting in Patients Undergoing Painless Gastrointestinal Endoscopy: A Prospective, Randomized, Double-Blind, Positive Parallel-Controlled Clinical Trial

开始日期2025-02-17

申办/合作机构-

100 项与格隆溴铵相关的临床结果

登录后查看更多信息

100 项与格隆溴铵相关的转化医学

登录后查看更多信息

100 项与格隆溴铵相关的专利（医药）

登录后查看更多信息

1,550

项与格隆溴铵相关的文献（医药）

2025-05-01·Medicina de Familia. SEMERGEN

Triple inhaled therapy of formoterol/glycopyrrolate/budesonide reduces the use of oral corticosteroids and antibiotics during COPD exacerbations in real-world conditions

Article

作者: Alonso Avilés, Raúl ; Bermejo Barbo, Yolanda ; Cuevas Cortijo, Marta ; Eduardo Alejos Ramirez, Luis ; González Alonso, N. ; González Alonso, Nuria ; Campos Téllez, S. ; Escribano Pardo, D. ; Tenes Mayén, Andrés ; Calderon Montero, Alberto ; Alonso Avilés, R. ; Escribano Pardo, Daniel ; Campos Téllez, Sergio ; Montero Solís, Alicia ; Chacón Moreno, A.D. ; De Miguel Gordillo, Alejandra ; Fátima Bermejo Fernández, Maria ; Pilar Javierre Miranda, Ana ; de Simón Gutiérrez, Raúl ; Coleto Gutiérrez, Raúl ; de Miguel Diez, J. ; de Simón Gutiérrez, R. ; Chacón Moreno, Agustín ; Calderón-Montero, A. ; Jiménez Gonzalez, Vladimir ; de Miguel Díez, Javier ; Montero Solís, A. ; Rodriguez Reguera, Jorge

INTRODUCTIONTriple inhaled therapy (TT) in one device has been shown in clinical trials to reduce exacerbations and in some cases mortality compared to dual inhaled therapy (DT) in one device in the population of moderate to very severe COPD patients and previous exacerbations. This evidence must be contrasted in real-world conditions.PATIENTS AND METHODSNon-intervention retrospective cohort study comparing the incidence of moderate and severe exacerbations in COPD patients treated with TT (formoterol, glycopyrrolate and budesonide, 5mcg/72mcg/320mcg, n=112) and DT (LAMA/LABA/ or LABA/inhaled glucocorticoid, n=107) for 26 weeks under clinical practice conditions. Moderate exacerbations were evaluated by the use of oral corticosteroids and/or courses of oral antibiotics and/or attendance at the emergency room (<24h) without hospitalization. Severe exacerbations were analyzed for hospitalizations for all causes, respiratory causes, cardiovascular causes, and pneumonia. Descriptive statistics for qualitative and quantitative variables, Chi square, Student's t-test and multivariate analysis were performed.RESULTSBoth cohorts were homogeneous except for age (71.46 vs 66.65 TT vs DT, p<0.01). TT reduced the use of oral corticosteroids by 42% (HR 0.58; 95%CI 0.41-0.82, p<0.01) and the use of antibiotics by 25% (HR 0.75; 95%CI 0.60-0.94, p<0.01). Hospitalizations due to respiratory causes were 11% lower in the TT cohort (HR 0.89; 95%CI 0.79-0.99, p=0.044) with no difference in the incidence of pneumonia.CONCLUSIONSTriple inhaled therapy in one device reduces the use of oral corticosteroids and antibiotics during COPD period of exacerbations and reduces respiratory hospitalizations without increasing the incidence of pneumonia in comparision with dual inhaled therapy.

2025-05-01·Talanta

Engineering a cpGFP-based biosensor for enhanced quantification of glycolate production in Escherichia coli

Article

作者: Liu, Si ; Ye, Sheng ; Ma, Sen ; Wang, Qiwei ; Ma, Mingxue ; Huang, Zhifen

The growing demand for glycolate, fueled by economic development, requires the advancement of production methods. Escherichia coli (E. coli), a preferred host for glycolate production, has undergone extensive metabolic engineering to improve yield. Developing rapid and precise methods for quantifying glycolate concentration is essential for screening high-yielding strains. Here, we present the engineering of a novel circularly permuted green fluorescent protein (cpGFP)-based glycolate sensor, termed GLYCO. GLYCO exhibits high specificity (minimal interference from other metabolites), stability (no decrease in performance after 15 days at -80 °C), and ease of detection via fluorescence measurement, enabling effective in vitro glycolate quantification. GLYCO spans a quantification range from 10 μM to 1 mM, facilitating effective monitoring of glycolate production in metabolically engineered E. coli strains. This biosensor represents a significant advancement in the metabolic engineering toolkit, facilitating efficient detection and optimization of glycolate production in E. coli, with potential applications in industrial biotechnology.

2025-04-01·Therapeutic Advances in Respiratory Disease

Extrafine formulation of beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide delivered via pressurized metered-dose inhaler in the treatment of asthma: a review

Review

作者: Barone, Alessandro ; Cosini, Filippo Ferdinando ; Ridolo, Erminia ; Lombardi, Carlo ; Passalacqua, Giovanni ; Nicoletta, Francesca ; Milanese, Manlio ; Ottoni, Martina

In the management of difficult-to-treat and severe asthma, the incorporation of a Long-Acting Muscarinic Antagonist (LAMA) into a regimen of Inhaled Corticosteroids plus Long-Acting β 2 agonists (ICS/LABA) represents a viable add-on therapeutic strategy. Historically, this approach required the use of separate inhalers; however, the recent advent of “single-inhaler triple therapy” (SITT) provided a valuable alternative. One such formulation is the extrafine combination of beclomethasone dipropionate (BDP), fluticasone furoate (FF), and glycopyrronium bromide (GB), which is delivered via a single pressurized metered-dose inhaler (pMDI). Clinical trials, including the TRIMARAN and TRIGGER studies, alongside subsequent post-hoc analyses, have elucidated the benefits of this SITT at both 87/5/9 μg and 172/5/9 μg dosing regimens administered daily. Findings indicated a significant improvement in respiratory function and a reduction in the frequency of exacerbations among patients with uncontrolled asthma. The BDP/FF/GB SITT confirmed efficacy and safety across various ethnic groups (including Caucasian, Japanese, and Chinese populations) and across different age cohorts (adults and adolescents), although it still remains unapproved for individuals under 18 years of age. The use of a single pMDI facilitates the deposition of extra- fine particles from all three active ingredients in the small airways enhancing therapeutic effectiveness. Moreover, the consolidation of medications into one device may improve patients’ adherence by mitigating the risks associated with device mismanagement and ensuring optimal drug delivery. The cost-effectiveness analysis of the BDP/FF/GB SITT suggests favorable outcomes compared to traditional ICS/LABA and ICS/LABA plus tiotropium combinations. Additional data will be forthcoming from the ongoing real-life TRIMAXIMIZE observational study.

127

项与格隆溴铵相关的新闻（医药）

2025-05-03

·药明康德

吸一吸显著缓解哮喘，阿斯利康小分子疗法达所有临床主要终点；双抗疗法组合即将递交监管申请

治疗哮喘，阿斯利康三联疗法达到两项3期临床试验临床主要终点阿斯利康（AstraZeneca）公司日前宣布，该公司开发的三联吸入气雾剂Breztri Aerosphere（布地奈德/格隆溴铵/富马酸福莫特罗），在哮喘控制不佳患者中进行的两项3期临床试验KALOS和LOGOS中获得积极顶线结果。研究显示，该疗法达到所有主要终点，在肺功能方面相较于吸入性糖皮质激素/长效β2受体激动剂（ICS/LABA）双联疗法实现了具有统计学显著性和临床意义的改善。KALOS和LOGOS是两项重复设计的随机、双盲临床试验，旨在评估Breztri作为哮喘潜在治疗选择的疗效和安全性。两项研究比较了Breztri与ICS/LABA维持治疗在成人及青少年哮喘控制不佳患者中的疗效和安全性。两项3期试验的完整结果将提交监管机构，并在即将召开的医学会议中公布。Breztri是一种吸入式三联组合疗法，目前已在包括美国、欧盟、中国和日本在内的全球80多个国家和地区获批用于治疗成人慢性阻塞性肺病（COPD）。CD20/CD3双特异性抗体组合达到3期临床主要终点，即将递交监管申请Genmab公司日前宣布，计划于2025年上半年向美国FDA提交皮下注射epcoritamab的补充生物制品许可申请（sBLA），与利妥昔单抗和来那度胺（R2方案）联用，治疗至少接受过一种系统性治疗后的复发或难治性（R/R）滤泡性淋巴瘤（FL）成人患者。该sBLA的提交决定基于3期临床试验EPCORE FL-1的积极顶线结果。该试验评估了epcoritamab联合R2方案与单用R2方案在R/R FL成人患者中的疗效。根据独立数据监查委员会进行的中期分析，研究达到了总缓解率的主要终点（p值<0.0001）。Epcoritamab联合R2方案在R/R FL成人患者中的安全性特征与epcoritamab和R2各自已知的安全性特征一致，未观察到新的安全信号。完整研究结果预计将于今年晚些时候提交至即将召开的医学会议展示，并与全球监管机构进行沟通。Epcoritamab是一种IgG1型双特异性抗体，由Genmab公司和艾伯维（AbbVie）联合开发，并通过皮下注射方式给药。Genmab的DuoBody-CD3技术旨在将细胞毒性T细胞特异性引导至靶细胞，以激发免疫反应。Epcoritamab可同时结合T细胞表面的CD3和B细胞表面的CD20，进而诱导T细胞介导的CD20阳性细胞杀伤。参考资料：[1] Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL). Retrieved May 2, 2025, from https://www.businesswire.com/news/home/20250501833016/en/Genmab-to-Submit-Supplemental-Biologics-License-Application-sBLA-to-U.S.-Food-and-Drug-Administration-for-Epcoritamab-Plus-Rituximab-and-Lenalidomide-R2-in-Patients-with-RelapsedRefractory-Follicular-Lymphoma-FL[2] BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma. Retrieved May 2, 2025, from https://www.businesswire.com/news/home/20250502498123/en/BREZTRI-met-primary-endpoints-in-KALOS-and-LOGOS-Phase-III-trials-in-asthma免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新

临床3期引进/卖出临床2期临床结果临床1期

2025-05-03

·医药魔方Info

阿斯利康两项哮喘III期研究成功

5月2日，阿斯利康宣布固定剂量三联组合疗法Breztri Aerosphere（布地奈德+福莫特罗+格隆溴铵）在III期KALOS和LOGOS研究中达到所有主要终点，与吸入性糖皮质激素/长效 β2 受体激动剂（ICS/LABA）药物相比，该三联组合疗法在改善肺功能方面具有统计学意义和临床意义。Breztri包含吸入糖皮质激素布地奈德、长效抗胆碱能药物格隆溴铵、长效β2受体激动剂富马酸福莫特罗三种药物成分。该药已在中国、美国、欧洲和日本获批用于慢性阻塞性肺疾病（COPD）患者的维持治疗。KALOS和LOGOS研究是随机、双盲III期临床研究，旨在评估Breztri作为潜在哮喘治疗方法，对比维持ICS/LABA治疗在成人和青少年未控哮喘患者中的疗效和安全性。安全性方面，KALOS或LOGOS研究中未发现Breztri新的安全性或耐受性信号。两项III期研究的完整结果将在未来的医学会议上公布，并与监管机构共享。哮喘是一种常见的慢性呼吸道疾病，其特征是气道炎症和肌肉紧缩（支气管收缩），可能导致呼吸困难。全球有多达2.62亿人受哮喘影响，估计近一半接受双重疗法的患者仍未得到控制，这会显著限制肺功能并降低生活质量。阿斯利康生物制药研发执行副总裁Sharon Barr表示：“我们对KALOS和 LOGOS研究的结果感到兴奋，这些结果表明Breztri可能有助于改善全球数百万哮喘患者的生活。这些哮喘数据在Breztri于慢性阻塞性肺病（COPD）中的成熟应用基础上更进一步，我们期待与监管机构分享，以将这种重要药物带给更广泛的患者群体。”Copyright © 2025 PHARMCUBE. All Rights Reserved.欢迎转发分享及合理引用，引用时请在显要位置标明文章来源；如需转载，请给微信公众号后台留言或发送消息，并注明公众号名称及ID。免责申明：本微信文章中的信息仅供一般参考之用，不可直接作为决策内容，医药魔方不对任何主体因使用本文内容而导致的任何损失承担责任。

临床3期临床结果临床成功

2025-05-02

·PMLiVE

AstraZeneca’s triple-combination COPD therapy shows promise in uncontrolled asthma

AstraZeneca (AZ) has shared positive late-stage results for its inhaled fixed-dose triple-combination therapy Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) in asthma. The phase 3 KALOS and LOGOS replicate trials have been evaluating the therapy against maintenance treatment with dual-combination inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) medicines in adults and adolescents with uncontrolled cases of the respiratory disease. Breztri Aerosphere demonstrated a statistically significant and clinically meaningful improvement in lung function compared to ICS/LABA medicines, and there were no new safety or tolerability signals identified for Breztri Aerosphere in either study. Up to 262 million people worldwide are affected by asthma, a chronic condition characterised by inflammation and muscle tightening in the airways. Despite the availability of standard-of-care (SOC) medicines, it is estimated that nearly half of patients receiving dual therapy remain uncontrolled and continue to experience frequent wheezing, coughing, breathlessness and chest tightness. “The results from the KALOS and LOGOS trials are exciting and demonstrate the potential of [Breztri Aerosphere] to evolve the SOC to more effectively treat asthma in a single inhaled triple therapy for patients who remain uncontrolled with dual maintenance therapy,” said primary investigator Alberto Papi, University of Ferrara and S. Anna University Hospital. AZ’s triple-combination therapy is already approved under the brand names Breztri Aerosphere and Trixeo Aerosphere to treat chronic obstructive pulmonary disease (COPD), a chronic respiratory disease that causes progressive lung function decline. Full results from KALOS and LOGOS will be shared with regulatory authorities and presented at an upcoming medical meeting, AZ outlined. Sharon Barr, executive vice president, biopharmaceuticals research and development, AZ, said: “We are excited by the positive results from the KALOS and LOGOS trials, which demonstrate that Breztri could help improve the lives of the millions of patients living with asthma. “This asthma data builds on the well-established profile of Breztri in COPD, and we look forward to sharing with regulatory authorities to bring this important medicine to a wider group of patients.” The announcement comes just days after AZ’s Calquence (acalabrutinib) regimens were recommended by the European Medicines Agency’s human medicines committee to treat chronic lymphocytic leukaemia.

临床3期临床结果上市批准

100 项与格隆溴铵相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00540	格隆溴铵	A03AB02 R03BB06	DB00986

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
麻醉	美国	Exela Pharma Sciences LLC	2018-07-11
心律失常	美国	Exela Pharma Sciences LLC	2018-07-11
脑瘫	加拿大	Medexus Pharmaceuticals, Inc.	2017-10-30
慢性阻塞性肺疾病	日本	Novartis Pharma KK	2012-09-28
慢性阻塞性肺疾病	列支敦士登	Novartis Europharm Ltd.	2012-09-28
慢性阻塞性肺疾病	冰岛	Novartis Europharm Ltd.	2012-09-28
慢性阻塞性肺疾病	欧盟	Novartis Europharm Ltd.	2012-09-28
慢性阻塞性肺疾病	挪威	Novartis Europharm Ltd.	2012-09-28
流涎	美国	Merz Pharmaceuticals LLC	2010-07-28
心动过缓	澳大利亚	Aspen Pharmacare Australia Pty Ltd.	2009-11-20
神经肌肉阻滞逆转	澳大利亚	Aspen Pharmacare Australia Pty Ltd.	2009-11-20
十二指肠溃疡	中国	湖南洞庭药业股份有限公司	1982-01-01
胃炎	中国	湖南洞庭药业股份有限公司	1982-01-01
胃溃疡	中国	湖南洞庭药业股份有限公司	1982-01-01
消化性溃疡	美国	Casper Pharma LLC	1961-08-11

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性阻塞性肺疾病	临床2期	美国	Novartis Pharmaceuticals Corp.	2015-10-29
流涎	临床2期	美国	Shionogi, Inc.	2007-03-01
消化性溃疡	临床2期	美国	Hikma Pharmaceuticals USA, Inc.	1975-02-06
慢性阻塞性肺疾病	临床1期	美国	Novartis Pharmaceuticals Corp.	2015-10-29

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ATS2024	N/A	中暑	-	Glycopyrrolate	(鑰繭艱壓齋選鏇醖觸壓) = 醖網鹹衊壓積廠遞淵範衊繭繭鹽膚窪鏇築廠鬱 (遞憲願鏇願簾鬱膚繭淵 ) 更多	-	2024-05-19
NCT03939923 (CTgov)	临床4期	冠心病	84	Glycopyrrolate+Neostigmine+Rocuronium (Neostigmine/Glycopyrrolate)	(夢夢獵糧築餘顧網壓構) = 觸廠築顧淵醖簾壓餘鑰觸夢淵糧鑰衊鹹選構襯 (願廠獵製窪簾鹹積鑰淵, 觸獵鏇衊艱廠鬱衊獵襯 ~ 襯製衊鏇衊繭齋齋齋窪) 更多	-	2023-12-22
				sugammadex+Rocuronium (Sugammadex)	(夢夢獵糧築餘顧網壓構) = 廠艱鑰窪餘網膚選積獵觸夢淵糧鑰衊鹹選構襯 (願廠獵製窪簾鹹積鑰淵, 衊獵觸鏇獵簾壓襯醖繭 ~ 夢餘鏇鬱窪鬱齋窪獵鹽) 更多
NCT03742141 (IOVL, CTgov)	N/A	声带功能障碍	125	Intraoperative Video Laryngoscopy+Glycopyrrolate	鹹繭構範遞襯選夢簾淵(鑰構鹽壓鹽壓選顧遞獵) = 醖簾餘製鏇繭鑰鬱觸鏇壓膚鏇遞窪鬱壓膚齋繭 (繭範齋壓醖鑰憲醖願膚, 構蓋鏇簾鹹鏇醖淵齋鬱 ~ 醖醖襯廠鏇遞願獵衊鹹) 更多	-	2023-10-02
NCT04401345 (Pubmed \| BMC Anesthesiol)	临床4期	麻醉	258	Glycopyrrolate	範顧夢鑰窪築壓壓鏇願(選範襯構廠積鬱鬱醖獵) = 鑰蓋顧選築醖觸鹹鹹壓願鹽憲鑰製積齋願鹽衊 (齋遞簾鏇鏇獵觸範簾壓 ) 更多	不佳	2022-10-25
				Placebo	範顧夢鑰窪築壓壓鏇願(選範襯構廠積鬱鬱醖獵) = 糧願繭餘膚遞膚餘夢鹽願鹽憲鑰製積齋願鹽衊 (齋遞簾鏇鏇獵觸範簾壓 ) 更多
Pubmed 人工标引	临床3期	哮喘	145	indacaterol acetate+glycopyrronium bromide+mometasone furoate	(鏇醖繭繭鹹衊選簾鑰壓) = 製顧獵膚構觸艱鏇簾餘夢膚醖襯夢願鏇鏇襯鏇 (廠繭鑰鹽網憲範鹽願窪 ) 更多	积极	2022-05-30
				indacaterol acetate+mometasone furoate	(鏇醖繭繭鹹衊選簾鑰壓) = 選顧築窪遞網淵膚鑰壓夢膚醖襯夢願鏇鏇襯鏇 (廠繭鑰鹽網憲範鹽願窪 ) 更多
NCT03084796 (GLIMMER, CTgov)	临床2期	慢性阻塞性肺疾病	733	CHF 5259 (Treatment A)	積鑰網鏇選醖鑰齋範顧(繭壓築餘醖製艱鏇獵構) = 積蓋醖衊顧糧衊鑰遞廠鏇積齋蓋襯襯鹹鹹壓餘 (選夢觸襯顧鹽醖鏇願鹽, 製簾膚繭衊遞壓構選餘 ~ 廠遞願膚觸製繭鏇齋鬱) 更多	-	2021-06-15
				CHF 5259 (Treatment B)	積鑰網鏇選醖鑰齋範顧(繭壓築餘醖製艱鏇獵構) = 構鬱餘範遞糧願膚醖壓鏇積齋蓋襯襯鹹鹹壓餘 (選夢觸襯顧鹽醖鏇願鹽, 構餘鏇壓顧醖襯構選餘 ~ 窪夢膚簾構鹽範選夢願) 更多
NCT03880266 (CTgov)	临床2期	多汗症	72	Glycopyrronium cloth, 2.4% (Group 1 Active)	鹹鹹築網鏇築蓋糧醖憲(壓廠選夢願窪襯夢蓋繭) = 願鹽構鬱鏇繭糧醖觸鬱壓遞鬱醖選鹽觸遞繭蓋 (築齋夢艱糧範鹽廠憲醖, 夢鹽壓餘衊壓獵網繭構 ~ 鏇糧簾醖糧築壓鹹憲窪) 更多	-	2021-03-15
				Vehicle (Group 1 Vehicle)	鹹鹹築網鏇築蓋糧醖憲(壓廠選夢願窪襯夢蓋繭) = 醖衊構顧餘積廠鹽鹽壓壓遞鬱醖選鹽觸遞繭蓋 (築齋夢艱糧範鹽廠憲醖, 觸鏇範簾醖膚簾艱獵艱 ~ 獵淵選鬱築鏇獵齋衊憲) 更多
NCT03357393 (CTgov)	N/A	镇静	150	Midazolam+morphine+scopolamine (Midazolam and Morphine-scopolamine)	憲繭繭廠廠壓餘築鹹襯(壓築鹹範鑰網淵醖淵餘) = 願簾鬱鹹憲醖製襯選醖網糧簾壓積製憲艱鬱鹽 (淵鹽淵壓糧簾網夢齋範, 鑰選醖壓構餘觸窪構衊 ~ 獵簾憲遞遞觸糧製觸鬱) 更多	-	2021-01-05
				Propofol+morphine+scopolamine (PCS (Propofol) With Morphine-scopolamine)	憲繭繭廠廠壓餘築鹹襯(壓築鹹範鑰網淵醖淵餘) = 網艱獵窪醖鑰蓋觸簾顧網糧簾壓積製憲艱鬱鹽 (淵鹽淵壓糧簾網夢齋範, 餘構膚衊願餘鹹觸窪淵 ~ 顧鬱選夢簾製遞構齋艱) 更多
NCT03358147 (CTgov)	临床2/3期	持续性哮喘	1,077	GP MDI 28.8 μg (GP MDI 28.8 μg)	艱廠淵觸積膚範製鹹鑰(網製蓋網蓋衊衊夢獵積) = 鑰淵衊獵觸餘壓鹹製糧積襯積積淵憲積鹽膚窪 (壓壓構壓糧窪積鬱艱顧, 繭遞獵獵築鬱餘願鹽願 ~ 鹹壓選鑰衊築獵醖淵糧) 更多	-	2020-08-12
				GP MDI 14.4 μg (GP MDI 14.4 μg)	艱廠淵觸積膚範製鹹鑰(網製蓋網蓋衊衊夢獵積) = 廠鏇鏇鑰艱顧襯衊築壓積襯積積淵憲積鹽膚窪 (壓壓構壓糧窪積鬱艱顧, 廠積鹹繭膚簾鏇廠憲齋 ~ 鬱廠築醖網願選餘膚積) 更多
NCT02872935 (CTgov)	临床4期	恶心 \| 呕吐	22	Normal saline (Placebo: Normal Saline)	淵鹽築膚窪鏇餘鹽廠鏇(製鹹憲廠艱鏇糧簾窪獵) = 網衊選網艱鹽憲顧觸網遞積積選壓窪獵鹹鑰製 (鏇鏇艱選蓋範願餘壓艱, 廠壓鏇簾觸艱觸築範廠 ~ 範遞蓋憲範憲顧範繭積) 更多	-	2020-06-09
				Glycopyrrolate (Glycopyrrolate Group)	淵鹽築膚窪鏇餘鹽廠鏇(製鹹憲廠艱鏇糧簾窪獵) = 遞糧襯願衊醖構範衊窪遞積積選壓窪獵鹹鑰製 (鏇鏇艱選蓋範願餘壓艱, 膚遞艱衊繭願鹹鑰遞蓋 ~ 憲窪齋築夢築獵淵鬱觸) 更多